

# Hamza Hashmi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4373026/publications.pdf>

Version: 2024-02-01

36  
papers

183  
citations

1307594

7  
h-index

1199594

12  
g-index

36  
all docs

36  
docs citations

36  
times ranked

285  
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of long-term corticosteroids in patients treated with CAR T-cell therapy. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 473-476.	0.9	2
2	Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. <i>Blood Advances</i> , 2022, 6, 486-494.	5.2	25
3	Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 109.e1-109.e8.	1.2	12
4	“Save the day with a Stem Cell Rescue™”: Use of autologous hematopoietic stem cell boost for hematopoietic recovery after CAR T cell therapy. <i>Bone Marrow Transplantation</i> , 2022, 57, 504-506.	2.4	5
5	ANDROMEDA: Dara-VCd for newly diagnosed AL amyloidosis: the next galaxy or a new standard of care?. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 445-447.	3.1	0
6	“Fast but not so Furious™”: Short observation time after subcutaneous Daratumumab administration is both a safe and cost-effective strategy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.4	2
7	Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie™s choice for patients with relapsed refractory multiple myeloma. <i>Expert Review of Hematology</i> , 2022, 15, 473-475.	2.2	10
8	Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8042-8042.	1.6	8
9	The ANDROMEDA Study: Is Daratumumab Plus CyBorDex the New Standard of Care for Newly Diagnosed AL Amyloidosis?. , 2021, 18, .		0
10	Carfilzomib-induced atypical haemolytic uraemic syndrome: a diagnostic challenge and therapeutic success. <i>BMJ Case Reports</i> , 2021, 14, e239091.	0.5	8
11	CD38-Directed Therapies for Management of Multiple Myeloma. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 201-211.	5.8	9
12	Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma. <i>Journal of Hematology (Brossard, Quebec)</i> , 2021, 10, 89-97.	1.0	5
13	Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature. <i>Annals of Hematology</i> , 2021, 100, 2155-2172.	1.8	4
14	Therapeutic roles of antibody drug conjugates (ADCs) in relapsed/refractory lymphomas. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2021, , .	0.9	1
15	Carfilzomib-Based 3-Drug Regimens for Newly Diagnosed Multiple Myeloma—All That Glitters Is Not Gold. <i>JAMA Oncology</i> , 2021, 7, 967.	7.1	0
16	The “comeback™” of Selinexor: From toxic to tolerable. <i>Current Problems in Cancer</i> , 2021, 46, 100789.	2.0	2
17	Efficacy and Safety of Regimens Used for the Treatment of POEMS Syndrome- A Systematic Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	4
18	Progress in research: Daratumumab improves treatment outcomes of patients with AL amyloidosis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 165, 103435.	4.4	2

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	0
20	Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4086-4090.	5.2	22
21	Role of hematopoietic cell transplantation in relapsed acute promyelocytic leukemia. <i>Clinical Transplantation</i> , 2020, 34, e14009.	1.6	3
22	Twice-daily intravenous bolus tacrolimus infusion: A safe and effective regimen for graft-versus-host disease prophylaxis. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 232-237.	0.9	1
23	Efficacy, Safety and Cost Implications of Outpatient Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma: A Single Center Experience. <i>Blood</i> , 2020, 136, 31-32.	1.4	3
24	Safety and Efficacy of Salvage Therapies for Relapse/Refractory AML/MDS after First Allogeneic Hematopoietic Stem Cell Transplant: A Systematic Review. <i>Blood</i> , 2020, 136, 3-4.	1.4	1
25	Safety and Efficacy of Tyrosine Kinase Inhibitors in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>Blood</i> , 2020, 136, 18-18.	1.4	1
26	Efficacy and Safety of Regimens Used for the Treatment of POEMS Syndrome- a Systematic Review. <i>Blood</i> , 2020, 136, 7-7.	1.4	0
27	Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy. <i>British Journal of Haematology</i> , 2019, 187, e35-e38.	2.5	35
28	Acquired factor X deficiency in a patient with multiple myeloma: a rare case highlighting the significance of comprehensive evaluation and the need for antimyeloma therapy for bleeding diathesis. <i>BMJ Case Reports</i> , 2019, 12, e230249.	0.5	6
29	Diffuse Hyperpigmentation in a Patient With an Axillary Mass. <i>JAMA Oncology</i> , 2019, 5, 1215.	7.1	0
30	Rare case of Bing-Neel syndrome treated successfully with ibrutinib. <i>BMJ Case Reports</i> , 2019, 12, e230067.	0.5	4
31	Skin nodules in a young patient with HIV/AIDS. <i>BMJ Case Reports</i> , 2019, 12, e231096.	0.5	0
32	Choosing the appropriate salvage therapy for B-cell non-Hodgkin lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1631-1634.	1.8	3
33	Primary Effusion Lymphoma without an Effusion: A Rare Case of Solid Extracavitary Variant of Primary Effusion Lymphoma in an HIV-Positive Patient. <i>Case Reports in Hematology</i> , 2018, 2018, 1-5.	0.4	3
34	A Rare Case of Erdheim-Chester Disease (Non-Langerhans Cell Histiocytosis) with Concurrent Langerhans Cell Histiocytosis: A Diagnostic and Therapeutic Challenge. <i>Case Reports in Hematology</i> , 2018, 2018, 1-6.	0.4	2
35	Clinical Outcomes Using Mycophenolate and Tacrolimus for Graft Versus Host Disease Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplant: A Single Institution Experience. <i>Blood</i> , 2018, 132, 5728-5728.	1.4	0
36	Safety and tolerability of lenalidomide maintenance dosing in patients with multiple myeloma post-autologous stem cell transplant. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522211123.	0.9	0